Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021092172 - FUNCTIONALLY MODIFIED MAYTANSINOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF

Publication Number WO/2021/092172
Publication Date 14.05.2021
International Application No. PCT/US2020/059109
International Filing Date 05.11.2020
IPC
A61K 31/33 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
A61K 31/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 47/50 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
C07D 401/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
C07D 405/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
C07D 471/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US]/[US]
  • UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US]/[US]
Inventors
  • XIE, Jin
  • KUMAR, Anil
  • LI, Zibo
Agents
  • RAYMOND, Adam S.
  • SHYNTUM, Yvonne Y.
  • YONGYE, Austin B.
  • MONHEIT, Rivka D.
  • HODGES, Robert A.
  • PABST, Patrea L.
  • SARGSYAN, S. Anna
  • ZUNIGA, Carlos A.
  • XU, Xiaojin
Priority Data
62/931,05805.11.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FUNCTIONALLY MODIFIED MAYTANSINOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF
(FR) MAYTANSINOÏDES MODIFIÉS DE MANIÈRE FONCTIONNELLE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
Abstract
(EN)
Radiosensitizer prodrugs and formulations and methods of use thereof are provided. Typically, the radiosensitizer prodrug is an analog of a radiosensitizer parent compound having one or more S-nitrosothiol moieties. Typically, the S-N bond of the S-nitrosothiol moiety can be cleaved by radiation during radiotherapy, releasing the parent compound and nitric oxide. One or preferably both the parent compound and the nitric oxide can contribute to death of tumor cells exposed to radiotherapy. Nanoparticle formulations for delivery of the prodrug, and methods of using them in combination with radiotherapy to treat tumors and cancer are also provided.
(FR)
L'invention concerne des promédicaments radiosensibilisateurs, des formulations et des procédés d'utilisation associés. Typiquement, le promédicament radiosensibilisateur est un analogue d'un composé parent radiosensibilisateur ayant une ou plusieurs fractions S-nitrosothiol. Typiquement, la liaison S-N de la fraction S-nitrosothiol peut être clivée par un rayonnement pendant une radiothérapie, libérant le composé parent et l'oxyde nitrique. Un ou de préférence les deux, le composé parent et l'oxyde nitrique, peuvent contribuer à la mort de cellules tumorales exposées à la radiothérapie. L'invention concerne également des formulations de nanoparticules pour l'administration du promédicament, et des procédés d'utilisation de celles-ci en combinaison avec une radiothérapie pour traiter des tumeurs et un cancer.
Latest bibliographic data on file with the International Bureau